Breaking News: Ipsen (IPSEY) declared today that Dominique Laymand has been selected Senior Vice President, Chief Ethics and Compliance Officer for the Ipsen group, effective as of 16th of March. She will report directly to Marc de Garidel, Chairman and CEO of Ipsen. Dominique Laymand will be a member of the Chairman’s Committee.
Marc de Garidel, Chairman and CEO of Ipsen said: “We are very happy to welcome Dominique Laymand within our company. I am sure that her recognized expertise in ethics and compliance and international experience will bring additional strengths for the Ipsen Group”.
Insights about those healthcare sector stocks that gained during Friday’s trade, are depicted underneath:
Sunshine Heart Inc (NASDAQ:SSH)’s shares picked up 2.86%, and closed at $5.75, during the last trading session, soon after the news release that an early-stage medical device company, declared it has received unconditional approval from the FDA to conduct an interim analysis of COUNTER HF, the Company’s U.S. pivotal study. The COUNTER HF study is a prospective, randomized, multi-center, controlled study that evaluates the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. Integral to the COUNTER HF study is the assessment of C-Pulse’s unique balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations due to worsening heart failure.
“Recently’s declaration is a noteworthy achievement for the company as it offers the potential to dramatically reduce the development timeline for this important solution for heart failure. The FDA decision to approve this interim analysis is not only unconditional but also arrives earlier than the originally anticipated timeframe of end Q1 2015. We are grateful for the FDA’s rapid response to our submission and look forward to working with the Agency through the balance of the COUNTER HF study and on the development of the next generation, fully implantable C-Pulse system,” commented Dave Rosa, President and Chief Executive Officer of Sunshine Heart.
Sunshine Heart Inc (NASDAQ:SSH), is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has accomplished an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application.
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO), raised 7.02%, and closed at $0.550, soon after a company biopharmaceutical company focused on the development of monoclonal antibody therapeutics, declared that it presented at the BIO CEO & Investor Conference, and took part in an analyst-led fireside chat at the Leerink Partners 2015 Global Healthcare Conference in New York City, New York, on Thursday, February 12, 2015.
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO), is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a focus on cancer.
Venaxis, Inc. (NASDAQ:APPY), enhanced 10.20%, and closed at $0.540, soon after the news release that an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, declared that the Company hosted an investor conference call and talked about business matters, counting the recent FDA “Not Substantially Equivalent” response, on February 13, 2015, at 8:30 a.m. ET.
Venaxis, Inc. (NASDAQ:APPY), is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company’s rapid blood based test for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low probability for acute appendicitis, allowing for more conservative patient administration.
CEL-SCI Corporation (NYSEMKT:CVM), enhanced 8.79%, and closed at $1.04, soon after the news release that a research and development company, declared the Ministry of Health of the Republic of Belarus has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Belarus is the 21th country to approve CEL-SCI’s Phase III trial.
“This means that CEL-SCI has now reached a key milestone in this pivotal Phase III clinical trial, receiving clearance in the planned 20 countries in addition to the United States. Well over 10 countries have been added to the study since we dismissed the preceding clinical research organization (CRO).
CEL-SCI Corporation (NYSEMKT:CVM), work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. CEL-SCI believes that the best way may be to activate the immune system of patients before they have received surgery, radiation and/or chemotherapy.
